Skip to Content
Merck
CN
  • Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response.

Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response.

The Journal of clinical investigation (2019-12-10)
Mireia Uribe-Herranz, Stavros Rafail, Silvia Beghi, Luis Gil-de-Gómez, Ioannis Verginadis, Kyle Bittinger, Sergey Pustylnikov, Stefano Pierini, Renzo Perales-Linares, Ian A Blair, Clementina A Mesaros, Nathaniel W Snyder, Frederic Bushman, Constantinos Koumenis, Andrea Facciabene
ABSTRACT

Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitumor CD8+ T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-γ. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium propionate, ≥99.0%
Sigma-Aldrich
Neomycin trisulfate salt hydrate, powder
Supelco
Metronidazole, analytical standard
Sigma-Aldrich
Sodium butyrate, ≥98.5% (GC)
Sigma-Aldrich
Vancomycin hydrochloride from Streptomyces orientalis, ≥900 μg per mg (as vancomycin base)